**Core tip:** Peptic ulcer disease (PUD) is not uncommon in Africa. There is considerable heterogeneity in its prevalence with no clear geographical patterns. There are further differences in PUD within-country despite endemic *Helicobater pylori* infection. Most African tertiary-centre studies have higher prevalence of PUD when compared with western countries. One possible reason for its sustained prevalence is the significant use of non-steroidal anti-inflammatory drugs in local preparations. The prevalence of atrophic gastritis and intestinal metaplasia were similar or modestly higher over western countries but lower than those seen in Asia. Contrastingly, a comparatively low prevalence for gastric cancer is usually observed in African centres, although these rates might be underestimated.

INTRODUCTION
============

Gastroduodenal disease (GDD) was initially thought to be uncommon in Africa because of the lack of clinical data and the reported rarity of peptic ulcer surgery\[[@B1]\]. Suspicion of conventional medicine was also considered commonplace in some regions of Africa\[[@B2]\]. For instance, a study on the prevalence of dyspepsia in rural Northeastern Nigeria demonstrated that over 50% of dyspeptic patients sought medical help mainly from traditional healers\[[@B2]\]. These observations and tendancies are thought to have resulted in the reported prevalence of peptic ulcer disease (PUD) and gastric cancer (GCA) in Africa being significantly lower than that in other areas of the world\[[@B3]\].

The standard of care for diagnosis of PUD is typically through upper gastro-intestinal (GI) endoscopy with biopsy of any mucosal abnormality, including abnormal ulceration or polypoid lesion, a procedure that is also required for histopathological diagnosis of GCA. Imaging with computed tomography (CT), magnetic resonance imaging and endoscopic ultrasound, where available, are additional procedures to stage cancer for prognostic purposes. In most African countries, patients present at late disease stages because of the lack of universal access to optimal health infrastructure and varying culturally-influenced health seeking behaviour\[[@B2],[@B4]\]. This subsequently leads to a variety of empirical therapies for symptomatic individuals further delaying definitive diagnosis, and thereby contributing to the observed low prevalence of GDD in some areas\[[@B1],[@B5]\]. Following the increasing availability of flexible upper GI endoscopy over recent years, it has now become apparent that GDD is prevalent across the continent of Africa\[[@B1],[@B3]\]. Currently, in Ghana, there are endoscopic services and CT scan facilities in tertiary medical centres but not at most regional or district hospitals. The same situation is observed in Mozambique, where endoscopy services and CT scan is only available in the four central hospitals of the country. Despite some resources, there is still a lot to be done in improving healthcare coverage for many patients with GDD. His-tological data on GCA is scarce in Africa, yet there is significant data being reported on histopathological lesions which are risk factors for development of GCA, such as atrophic gastritis (AG) and intestinal metaplasia (IM)\[[@B4]\].

Recognised risk factors for GCA include *Helicobater pylori* (*H. pylori*), diet, lifestyle preferences, Epstein-Barr virus and industrial chemical exposure\[[@B6]\], while those for PUD are *H. pylori*, non-steroidal anti-inflammatory drug (NSAID)-use, smoking and alcohol consumption\[[@B7]\]. Of these, *H. pylori* infection is generally accepted to be causally related to the development of AG, IM and gastric and duodenal ulceration as well as distal GCA\[[@B8],[@B9]\]. The majority of patients with duodenal ulcer (DU) are infected with *H. pylori*. Distal GCA is strongly associated with lifelong *H. pylori* infection and relative socio-economic deprivation\[[@B10]\]. Proximal GCA has rather been linked to smoking, gastro-oesophageal reflux disease, obesity and medium-high socio-economic status\[[@B10]\]. Although infection is universally associated with gastritis, the development into a broad spectrum of clinical and endoscopic outcomes is dependent on a number of factors, including the susceptibility of the host, the virulence of the infecting strain, and environmental co-factors\[[@B11]\]. In Africa the association of *H. pylori* infection with GDD is rather complex; the infection has a high prevalence across the continent (80%-95%) irrespective of the period of birth\[[@B12]\]. However, there appears to be a low overall incidence of GCA, a situation that is known as the African enigma\[[@B10]\]. There is also a variable distribution of incidence of GDD in Africa which does not necessarily mirror the prevalence of *H. pylori*. For instance, in Western Africa, the prevalence of DU has been reported to be lower in the northern savannah in comparison with the coastal areas. Both regions have similar prevalence of *H. pylori* infection\[[@B13],[@B14]\]. In addition, the lack of population-based longitudinal studies also makes it difficult to evaluate the strength of association of GDD with risk factors like *H. pylori* in Africa.

This review analyses the patterns of incidence of PUD, gastric histopathological lesions and GCA in Africa. We compare patterns of GDD obtained with endoscopy with new data obtained on pre-malignant gastric histopathological lesions in Accra Ghana and Maputo Mozambique; data in Accra, Ghana are newly presented in this review and lend support to the discussion on the concept of the *H. pylori* African enigma.

SOURCES
=======

We performed a literature review using the online databases PubMed and African Journals online. Articles were considered if they had "gastro-duodenal disease", "peptic ulcer", "gastric cancer" and "Africa" or "an African country" as keywords in the search. In relation to the histopathology, another search was made using "pre-malignant lesions", "gastric atrophy" and "intestinal metaplasia" as keywords. We did not identify purposely structured cohort studies to establish incidence of GDD and therefore studies were eligible for further analysis if they were endoscopy-based hospital or tertiary center studies of symptomatic or dyspeptic individuals referred for evaluation. The references and abstracts were checked to determine if they were eligible and to ensure they were comparable.

METHODS
=======

Symptomatic individuals undergoing upper gastrointestinal endoscopy based on clinical need were consecutively recruited at the Korle-Bu Teaching Hospital, the major tertiary centre in Accra. Patients' symptoms and endoscopic diagnoses were captured with the study questionnaire after informed consent. The *H. pylori* status of patients was determined by performing a rapid urease test (*i.e*., Campylobacter-Like Organism test) on gastric antral biopsy samples. Samples from the antrum, corpus and incisura angularis, as required by the updated Sydney system, were placed in separate specimen containers containing 10% formalin solution at endoscopy. *H. pylori* was identified by haematoxylin and eosin and warthin-starry staining and histologic gastritis was determined according to the updated Sydney system in the Histopathology Department, Leicester Royal Infirmary, Leicester, United Kingdom. A sample was defined as being positive for *H. pylori* if a PCR product was obtained for either a housekeeping gene (*ureI*, *yhpC*, p*pA*)\[[@B15],[@B16]\] or *glmM*\[[@B17]\] as previously described. Molecular studies were performed in the Department of Genetics, University of Leicester, United Kingdom.

PATTERNS OF PEPTIC ULCER DISEASE IN AFRICA
==========================================

In Africa, there is considerable heterogeneity in the prevalence of DU and gastric ulcer (GU) across the regions of the continent with no clear geographical pattern of PUD incidence (Table [1](#T1){ref-type="table"}). Furthermore, there are differences in peptic ulcer incidence within-country despite universally endemic *H. pylori* infection. In Ghana, Komfo-Anokye Teaching Hospital, Kumasi, which serves the central-northern regions, has a lower incidence of PUD in comparison with Korle-Bu Teaching Hospital, Accra, which serves the Southern regions of Ghana, (Accra: DU 19.6% *vs* Kumasi: DU 3%)\[[@B18]\]. Two studies in Nigeria had discordant PUD incidence: In Ibadan, Southern Nigeria, DU incidence was 2.3% relative to GU 9.3%, while Northern Nigeria had higher DU incidence 6.8% but lower GU incidence 2.7%\[[@B19],[@B20]\]. On the contrary, two separate tertiary health centres in Kenya, Nakuru and Nairobi, had similar DU incidence but different GU incidence (Nairobi: GU 8.5%, DU 9.8%; Nakuru: GU 1.9% DU 9.5%)\[[@B21]\]. We realize that these differences might be related with study characteristics such as age and gender distribution of the study population; or with intrinsic features related with study design\[[@B22]\]. However, mean age and sex differences were modest and did not reliably predict prevalence of PUD across these studies. For instance, a relatively low mean age was associated with both elevated and decreased PUD prevalence (*e.g*., compare Accra, Ghana with Nakuru, Kenya, Table [1](#T1){ref-type="table"}). Similarly, male populations had both higher and lower prevalence of PUD (e.g. compare Accra, Uganda with Mbarara, Uganda; Table [1](#T1){ref-type="table"}). Most of the African tertiary-center studies had higher prevalence of PUD when compared with similar studies in western countries such as the United States\[[@B23]\], Netherlands\[[@B24]\] and Italy\[[@B25]\], but the latter studies had considerably larger sample sizes (Table [1](#T1){ref-type="table"}). Additionally, it is also worth noting that hospital-based endoscopic studies with relatively small sample sizes in Africa are more likely to suffer selection bias with more advanced clinical presentations\[[@B26]\]. Nevertheless, in an unselected community study in Lusaka, Zambia\[[@B27]\], PUD was comparable in prevalence to other western countries (Table [1](#T1){ref-type="table"}).

###### 

Patterns of incidence of peptic ulcer disease in hospital-based endoscopic studies of dyspeptic patients

  **Country**                        **Year(s) of study**   **Mean age (yr)**   **Males**     **Females**     ***n***   **Incidence rate (%)**         
  ---------------------------------- ---------------------- ------------------- ------------- --------------- --------- ------------------------ ----- ---------
  Ibadan, Nigeria\[[@B19]\]          2008-2009              49.2 ± 13.8         39 (45.3)     47 (54.7)       86        2.3                      9.3   11.6
  Northern Nigeria\[[@B17]\]         2012                   49.5 ± 15           68 (46)       80 (54)         148       6.8                      2.7   9.5
  Mbarara, Uganda\[[@B39]\]          2014-2015              53.5 ± 17.8         110 (59.8)    74 (40.2)       184       3.8                      7.6   11.4
  Accra, Ghana\[[@B75]\]             1995-2002              43.7 ± 10.6         3777 (54.1)   3200 (45.9)     6977      19.6                     5.0   24.6
  Kumasi, Ghana\[[@B18]\]            2006-2011              \-                  1337 (43)     1773 (57)       3110      3.0                      4.7   7.7
  Nairobi, Kenya\[[@B21]\]           2011-2013              47.0                1368 (43.5)   1779 (56.5)     3147      9.8                      8.5   18.3
  Nakuru, Kenya\[[@B21]\]            2011-2013              42.0                1372 (46.7)   1564 (53.3)     2936      9.5                      1.9   11.4
  Kilimanjaro, Tanzania\[[@B76]\]    2009-2010              Median: 48.0        99 (47.6)     109 (52.4)      208       18.3                     5.8   24.1
  Lusaka, Zambia\[[@B27]\]           1999-2002              \-                  79 (35.7)     142 (64.3)      221       3.1                      0.5   3.6
  Rotterdam, Netherlands\[[@B24]\]   1996-2005              55.6 ± 17.9         9222 (46.1)   10,784 (53.9)   20006     3.5                      2.4   5.9
  Rome, Italy\[[@B25]\]              2005-2007              Median: 62.5        \-            \-              11148     1.8                      0.9   2.7
  United States\[[@B23]\]            1996-2005              \-                  \-            \-              6438      \-                       \-    1.5-3.0

DU: Duodenal ulcer; GU: Gastric ulcer.

Globally, PUD incidence has decreased over recent decades. This has been demonstrated by several population-based prospective studies in Europe (Netherlands\[[@B28]\], Spain\[[@B29]\], Belgium\[[@B30]\], United Kingdom\[[@B31]\]), North America (United States\[[@B32]\]) and Asia (India\[[@B33]\], Hong Kong\[[@B34]\], Taiwan\[[@B35]\]). Time trend prospective studies are however scarce in Africa. A retrospective descriptive study reported on patients who underwent upper GI endoscopy in the endoscopy unit of Obafemi Awolowo University Teaching Hospital, Ile-Ife, Nigeria, between January 2000 and December 2010\[[@B36]\]. Over the study period, 292 patients (15.8%) were diagnosed with DU. The prevalence of DU for 2000-2004 was 22.9% (*n* = 211 patients) compared with 9.2% (*n* = 81) for 2005-2010 (*P* \< 0.001)\[[@B36]\]. These prevalence rates were much lower than the 38.7% reported by Ndububa et al\[[@B37]\] for the years 1992-1999 at the same institution. In Uganda, two separate cross-sectional studies also showed reduction in DU prevalence from 18% in 2005\[[@B38]\] to 3.8% in 2014\[[@B39]\].

Overall, the data shows that the incidence of PUD has declined in many countries. Most likely this phenomenon is a result of the decrease in *H. pylori* infection, particularly in Western populations\[[@B40]\]. However, it is unclear the reasons for the decline in some African countries where *H. pylori* infection rates are still high. Management of PUD has improved substantially due to implementation of therapies for *H. pylori* and the introduction of proton pump inhibitors (PPIs) which are increasingly accessible globally. The continued occurrence of PUD is increasingly due, at least in part, to the widespread use of low-dose aspirin and NSAIDs, especially in Western countries and among older patients\[[@B37],[@B40]\]. A cross-sectional study of 242 dyspeptic patients in Accra, Ghana, evaluated the endoscopic spectrum of disease at a major tertiary centre\[[@B3]\]. A third (32.6%) of the study patients had a history of NSAID-use, especially as ingredients in local over-the-counter medicinal/herbal preparations\[[@B3]\]. In this study in Accra, there was an increased prevalence of DU in *H. pylori*-infected patients taking NSAIDs\[[@B3]\]. NSAID-use may therefore contribute to the varying PUD prevalence between and within countries in a *H. pylori* endemic continent such as Africa.

GASTRIC HISTOPATHOLOGY IN DYSPEPTIC PATIENTS
============================================

Gastric atrophy is an established risk factor for GCA\[[@B41]\]. Additionally, the risk of GCA increases with a greater extent and higher degree of AG\[[@B42]\]. Further studies suggest that IM is also a risk factor for GCA\[[@B43],[@B44]\]. Pre-malignant lesions, AG and IM, are not uncommon in tertiary center studies of symptomatic patients undergoing endoscopy in Africa. Excluding the 2007 study in Kenya by Kalebi et al\[[@B4]\], which detected an AG rate of 57%, most hospital-based endoscopic studies have shown prevalence rates of AG of 5%-38% and for IM of 4%-32% across populations in sub-Saharan Africa (Table [2](#T2){ref-type="table"}). These values were either similar to or had a modestly higher prevalence as compared to rates in western countries (*e.g*., Sweden, Finland or United States) but lower than those seen in Asia (Korea, China) (Table [2](#T2){ref-type="table"}).

###### 

Hospital-based endoscopic studies of pre-malignant lesions

  **Country**                                         **Study population**                      ***n***   **Gastric atrophy frequency (%)**      **Intestinal metaplasia frequency (%)**
  --------------------------------------------------- ----------------------------------------- --------- -------------------------------------- -----------------------------------------
  Cote d'Ivoire, Attia et al\[[@B77]\], 2001          Dyspeptic patients                        137       \-                                     19
  Sudan, El-Mahdi et al\[[@B78]\], 1998               Dyspeptic *H. pylori* infected patients   78        37                                     4
  Egypt, Abdel-Wahab et al\[[@B79]\], 1996            DU patients                               43        \-                                     26
  Gambia, Campbell et al\[[@B80]\], 2001              Dyspeptic patients                        45        10                                     12
  Uganda, Wabinga et al\[[@B81]\], 2005               Dyspeptic patients                        114       17                                     7
  Kenya, Kalebi et al\[[@B82]\], 2007                 Dyspeptic patients                        71        57                                     11
  Nigeria, Ndububa et al\[[@B83]\], 2007              DU and GC patients                        115       \-                                     32 GC
  16 DU                                                                                                                                          
  Jos, Nigeria, Tanko et al\[[@B52]\], 2008           Dyspeptic patients                        100       38                                     28
  Nigeria, Badmos et al\[[@B84]\], 2009               Dyspeptic patients                        1047      5                                      9
  Tunisia, Jmaa et al\[[@B85]\], 2010                 Dyspeptic patients                        352       35                                     11
  Ilorin, Nigeria, Badmos et al\[[@B86]\], 2010       Dyspeptic patients                        57        32                                     9
  Maputo, Mozambique Carrilho et al\[[@B46]\], 2009   Dyspeptic patients                        109       8.3                                    8.3
  United States, Almouradi et al\[[@B87]\], 2013      Symptomatic individuals                   437       \-                                     15.0[1](#T2FN1){ref-type="table-fn"}
  Finland, Eriksson et al\[[@B88]\], 2008             Symptomatic individuals                   505       \-                                     18.8 (antrum)
  7.1 (body)                                                                                                                                     
  Sweden, Borch et al\[[@B89]\], 2000                 Symptomatic individuals                   501       9.4[1](#T2FN1){ref-type="table-fn"}    
  Korea, Kim et al\[[@B90]\], 2008.                   Symptomatic individuals                   713       42.7 (antrum)                          42.5 (antrum)
  38.1 (body)                                         32.7 (body)                                                                                
  China, Zou et al\[[@B91]\], 2011                    Symptomatic individuals                   1,022     63.8[1](#T2FN1){ref-type="table-fn"}   
  Japan, Sakitani et al\[[@B47]\], 2011               Symptomatic individuals                   1395      \-                                     17.2 (antrum)
  10.8 (body)                                                                                                                                    

Prevalence of gastric atrophy or intestinal metaplasia in the antrum and/or body. DU: Duodenal ulcer; GU: Gastric ulcer; *H. pylori*: *Helicobater pylori*.

Gastric histopathology in Accra, Ghana and Maputo, Mozambique: A comparative analysis
-------------------------------------------------------------------------------------

The updated Sydney system of classification of gastritis emphasizes the importance of combining topographical, morphological and aetiological information into a scheme that helps to generate reproducible and clinically useful information\[[@B45]\]. It includes biopsies at the antrum\[[@B2]\], body\[[@B2]\] and incisura angularis\[[@B1]\]. Two such *H. pylori* studies in Africa comprehensively evaluated gastric histopathology and its relationship with *H. pylori* infection and gastric diseases (Table [3](#T3){ref-type="table"}). The first was a prospective descriptive study conducted at the Maputo Central Hospital, Mozambique that estimated the prevalence of *H. pylori*, chronic gastritis and IM in 109 consecutive dyspeptic patients who were eligible for upper GI endoscopy between 2005 and 2006\[[@B46]\]. The second was a new study at the Korle-Bu Teaching Hospital (KBTH), Accra, during which clinical and histopathological assessments were performed on 136 dyspeptic patients referred for upper GI endoscopy at the major tertiary centre between 2015 and 2016. The results of this latter study and comparisons with the Mozambique dataset are presented here.

###### 

Gastric histopathological lesions at the Korle Bu Teaching Hospital, Accra, Ghana and Maputo Central Hospital, Mozambique

                                                 **Accra, Ghana**   **Maputo, Mozambique**
  ---------------------------------------------- ------------------ ------------------------
  Total                                          136                109
  Median age (yr)                                52                 37
  Sex                                            *n* (%)            *n* (%)
  Female                                         61 (44.9)          74 (67.9)
  Male                                           75 (55.1)          35 (32.1)
  *H. pylori* prevalence:                                           
  Histology                                      54.4%              62.4%
  *H. pylori* prevalence:                                           
  PCR                                            93.3%              92.6%
  Active inflammation                            *n* (%)            *n* (%)
  Antrum                                         47 (34.6)          57 (53.8)
  Incisura                                       45 (37.2)          58 (54.2)
  Body                                           40 (29.9)          21 (31.3)
  Chronic inflammation                           *n* (%)            *n* (%)
  Antrum                                         115 (84.6)         100 (94.4)
  Incisura                                       97 (80.2)          99 (92.5)
  Body                                           97 (72.4)          57 (85.1)
  Pattern of gastritis                           *n* (%)            *n* (%)
  antral-predominant                             51 (37.5)          54 (49.5)
  Pangastritis (antrum and body)                 70 (51.5)          45 (41.3)
  Gastric atrophy                                *n* (%)            *n* (%)
  Antrum                                         5 (3.7)            2 (2.5)
  Incisura                                       7 (5.8)            6 (6.2)
  Body                                           3 (2.2)            1 (1.5)
  Intestinal metaplasia                          *n* (%)            *n* (%)
  Antrum                                         10 (7.3)           4 (3.8)
  Incisura                                       6 (5.0)            7 (6.5)
  Body                                           1 (0.7)            0 (0.0)
  Pre-malignant lesions                          *n* (%)            *n* (%)
  Gastric atrophy and/or intestinal metaplasia   20 (14.7)          15 (13.8)

*H. pylori*: *Helicobater pylori*.

Overall, the commonest histologic diagnosis in both centres was chronic inflammation (*i.e*., 84.6% in Accra and 90.8% in Mozambique) irrespective of location in the stomach\[[@B46]\]. Chronic infiltrates were detected in more than twice as many patients as opposed to active inflammation with neutrophilic activity, (Figure [1](#F1){ref-type="fig"}). Of the 136 patients sampled in Accra, 20 (14.7%) had evidence of pre-malignant lesions (atrophy and/or IM). The majority showed mild gastric atrophy 6/9 (66.7%; T1 score) or IM 10/16 (62.5%; M1 score), respectively, (see Table [4](#T4){ref-type="table"} for the overview data and Figure [2](#F2){ref-type="fig"} for an exemple of the tissue staining). Likewise, the prevalence of pre-malignant lesions, in a sample of 109 patients from Maputo, were 8.3% AG and 8.3% IM. Most of which were located distally, in the antrum or incisura angularis\[[@B46]\], as seen in KBTH, Accra. A study in Japan evaluated for gastric histopathological differences between antrum and body in 1395 patients, in a country where endoscopy is very accessible to patients due to high incidence of GCA\[[@B47]\]. This study reported the prevalence of IM as 17.2% and 10.8% in antrum and body respectively. IM in this Japanese study was considerably higher than that seen in Accra, Maputo and most African tertiary centre studies (Table [2](#T2){ref-type="table"}) where gastric pathology may be rather over-represented. Interestingly, in Finland, an European country with low *H. pylori* prevalence and GCA incidence, IM in the body, 7.1%, was higher than that seen in Accra and Maputo. Overall, there was a higher prevalence of IM in the gastric body of Japanese samples as compared to the Accra, Maputo and Finland samples. This is important as IM in the gastric body has been identified as an independent risk factor for GCA following multi-variate analysis\[[@B47]\].

![Chronic gastritis affecting the mucosa of the gastric antrum (Haematoxylin and eosin stain; Magnification × 100).](WJG-25-3344-g001){#F1}

![Gastric antral mucosa showing atrophy, intestinal metaplasia and mild chronic inflammation (Haematoxylin and eosin stain; Magnification × 100).](WJG-25-3344-g002){#F2}

###### 

Severity of atrophic gastritis and intestinal metaplasia at the Korle Bu Teaching Hospital, Accra, Ghana (*n* = 136), as per updated Sydney system

  **Atrophy (*n* = 9)**   **Metaplasia (*n* = 16)**        
  ----------------------- --------------------------- ---- -----------
  T1                      6 (66.7)                    M1   10 (62.5)
  T2                      2 (22.2)                    M2   5 (31.3)
  T3                      1 (11.1)                    M3   1 (6.2)

The prevalence of *H. pylori* in the sampled patients by histopathology in Accra was 54.4% with 74 out of 136 patients infected (see Table [3](#T3){ref-type="table"}; and Figure [3](#F3){ref-type="fig"} for a representative histopathological sample); whereas 93.3% had molecular evidence of *H. pylori* by PCR. Comparably, *H. pylori* was identified in 68 out of 109 cases (62.4%) based on histological assessment but 92.6% when assessed by PCR in the Mozambique study\[[@B46]\]. Furthermore, *H. pylori* was significantly more frequent when chronic inflammatory infiltrate, neutrophilic activity or degenerative surface epithelial damage were observed, regardless of the anatomic location\[[@B46]\]. It has been shown that *H. pylori* detection by histopathology may be more difficult in situations where the cellular environment may not be conducive for bacterial growth and/or when the bacterial load is very low. PCR is more sensitive as the grade of atrophy and/or IM progress toward malignancy\[[@B48]\]. Moreover, the accuracy of histopathology identification of *H. pylori* is affected by PPI and antibiotic use, which were not an exclusion criteria for these studies\[[@B49],[@B50]\].

![*Helicobacter pylori* infection. The organisms are indicated with arrows (Warthin-Starry stain; Magnification × 400).](WJG-25-3344-g003){#F3}

In Accra, demographically, patients with either gastric atrophy or IM were comparable but patients with pre-malignant lesions were more likely to be older than 50 years and male. However, no statistically significant differences were observed for the presence of IM and glandular atrophy according to *H. pylori* colonization in either Ghana or Mozambique\[[@B46]\]. In this histopathology study 3 (2.9%) patients had GCA in Accra with none represented in the Maputo study of 109 individuals. However, a recent study from Mozambique reported a prevalence of 1.5% from Maputo Central Hospital\[[@B51]\]. These low prevalence rates were comparable to similarly designed hospital-based studies in Nigeria (3.0%)\[[@B52]\] and Uganda (3.0%)\[[@B53]\].

Both studies (Accra and Maputo) demonstrated similar topographical distribution of *H. pylori* gastritis with antral involvement being the most common. In KBTH, Accra, antral gastritis was present in 89% (antral-predominant gastritis 37.5%, pan-gastritis (antrum and body) 51.5%, normal histology 11.0%). Chronic inflammation, lymphoid follicles, and neutrophilic activity were more frequent and of increased severity in the antrum and incisura than in the corpus\[[@B46]\]. There was no demonstrable significant relationship between the pattern of histologic gastritis and clinical gastric-duodenal disease. In general, the topographic distribution of acute *H. pylori* infection has been associated with specific gastro-duodenal phenotypes\[[@B54]\]. Infection of the antrum stimulates gastrin release which leads to increased acid production from parietal cells, resident mainly in the body\[[@B54]\]. This results in an elevated duodenal acid load, gastric metaplasia and subsequent duodenal ulceration\[[@B55]\]. On the other hand, patients with GU or GCA, have inflammation involving acid-secreting parietal cells of the body evolving with gastric atrophy and hypochlorhydria\[[@B56]\]. Essentially, an increase in acid secretion limits *H. pylori* gastritis to the antrum, increasing the risk of DU disease while a reduction in acid secretion allows more proximal inflammation and increases the risk of AG, GU, and GCA. Gastritis and atrophy negatively influence acid secretion\[[@B57]\]. Of note, both histopathologic studies demonstrate that antral inflammation was more common than body-gastritis in most infected individuals. As antral inflammation is known to be negatively associated with GCA\[[@B58]\], the high antral inflammation may explain the low prevalence of GCA in these populations.

GEOGRAPHICAL DISTRIBUTION OF GASTRIC CANCER ACROSS SUB-SAHARAN AFRICA
=====================================================================

GCA remains an important cancer worldwide and was estimated to be responsible for over 1000000 new cases in 2018 and an estimated 783000 deaths, *i.e.*, approximately 1 in every 12 deaths globally\[[@B59]\]. Consequentially it is the fifth most frequently diagnosed cancer and the third leading cause of cancer mortality\[[@B59]\]. Age-standardized incidence rates are significantly elevated in Eastern Asia (45.3 per 100000 persons/year), when compared with rates in Northern America (7.6 per 100000 persons/year) and Northern Europe (9.3 per 100000 persons/year)\[[@B59]\]. These relatively low incidence rates are comparable to those seen across many regions of Africa (Table [5](#T5){ref-type="table"}). The cumulative incidence rate up to and including an age of 74 years, expressed as a percentage of cancers of the stomach in sub-Saharan-Africa was 0.46% whereas the comparable worldwide rate was 1.39%\[[@B60]\].

###### 

Age-Standardized Incidence rates of gastric cancer in sub-Saharan Africa\[[@B60]\]

  **Region**                **Years of study**   **Age-standardized incidence rate (per 100000 person-years)**   **Total**   
  ------------------------- -------------------- --------------------------------------------------------------- ----------- ------
  Central Africa                                                                                                             
  Congo, Brazzaville        2009-2013            2.0                                                             1.5         3.5
  East Africa, Mainland                                                                                                      
  Ethiopia, Addis Ababa     2012-2013            3.0                                                             2.2         5.2
  Kenya, Eldoret            2008-2011            9.8                                                             7.9         17.7
  Kenya, Nairobi            2007-2011            9.2                                                             9.7         18.9
  Malawi, Blantyre          2009-2010            4.4                                                             3.5         7.9
  Mozambique, Beira         2009-2013            0.8                                                             0.4         1.2
  Uganda, Kampala           2008-2012            6.4                                                             3.3         9.7
  Zimbabwe, Bulawayo        2011-2013            4.8                                                             5.7         10.5
  Zimbabwe, Harare          2010-2012            18.7                                                            16.3        35.0
  East Africa, Islands                                                                                                       
  France Reunion            2011                 16.8                                                            6.3         23.1
  Mauritius                 2010-2012            7.0                                                             3.2         10.2
  Seychelles                2009-2012            3.7                                                             3.2         6.9
  Southern Africa                                                                                                            
  Botswana                  2005-2008            1.1                                                             0.4         1.5
  Namibia                   2009                 5.0                                                             2.0         7.0
  South Africa, National    2007                 4.0                                                             1.8         5.8
  South Africa, East Cape   2008-2012            1.4                                                             0.8         2.2
  Western Africa                                                                                                             
  Benin, Cotonou            2013-2015            11.3                                                            2.4         13.7
  Cote D'Ivoire, Abidjan    2012-2013            2.8                                                             2.8         5.6
  The Gambia                2007-2011            2.2                                                             0.8         3.0
  Guinea, Conakry           2001-2010            4.7                                                             2.8         7.5
  Mali, Bamako              2010-2014            19.1                                                            15.3        34.4
  Niger, Niamey             2006-2009            2.2                                                             1.6         3.8
  Nigeria, Abuja            2013                 4.4                                                             2.2         6.6
  Nigeria, Calabar          2009-2013            0.7                                                             1.4         2.1
  Nigeria, Ibadan           2006-2009            2.8                                                             1.3         4.1

About 24000 new cases of stomach cancer and 22000 deaths were estimated to have occurred in 2002 in Africa, with three quarters (18000 new cases) occurring in sub-Saharan Africa\[[@B60]\]. The national cancer registries with the highest recorded cumulative incidence rates are Harare (Zimbabwe), Bamako (Mali), Kenya, Réunion (France), Rwanda and Uganda\[[@B60]\] (Table [5](#T5){ref-type="table"}).

The significant decline in the incidence of non-cardia GCA in developed countries is an established phenomenon which is associated with improvements in food preservation and a decline in transmission of and infection by *H. pylori*\[[@B61]\]. On the contrary, no decrease was noted in rates of histologically diagnosed cases in South Africa between 1986 and 1995\[[@B60]\]. There is also no indication that the incidence of stomach cancer is declining in Africa; time trends for the cancer registries in Kampala (Uganda)\[[@B62]\], Harare (Zimbabwe)\[[@B63]\], and Bamako (Mali)\[[@B60]\] indicate little or no change in incidence during the past 20 years\[[@B60]\]. Notwithstanding, similar concerns remain about the data as encountered in the trends of PUD. In addition to late presentation and selection bias, cancer data in Africa is obtained from GLOBOCAN which is subsequently drawn from country cancer registries\[[@B4],[@B26]\]. Such registries are not comprehensive due to considerable variation in the availability of efficient local cancer reporting systems or databases, essential diagnostic health equipment (endoscopy, histopathology, imaging) and expertise\[[@B26]\]. Validation of cases and their source as well as specificity of outcome definitions are not explicit in most studies further contributing to uncertainty about the precise incidence rates of GCA on the continent\[[@B4],[@B22]\].

THE *HELICOBACTER PYLORI* AFRICAN ENIGMA
========================================

Helicobacter pylori infection is endemic in Africa, however GDD prevalence is reportedly low especially for GCA\[[@B64]\]. This phenomenon is referred to as the "African enigma"-a high prevalence of *H. pylori* with an apparently low incidence of GCA\[[@B13]\]. The concept was challenged based on the potential problems with the data upon which the theory was based. For example, in Africa, we cannot ignore major difficulties in access to healthcare, endoscopy and radiological examinations, all of which are deemed to have reduced the likelihood of a diagnosis of PUD and GCA\[[@B1]\]. On the contrary, patients with other common cancers such as oesophageal and cervical cancer are represented in hospitals in Africa so it remains curious why GCA patients would selectively not seek care\[[@B65]\].

Bacterial virulence has been studied to determine disease specific associations which might explain differences in GDD incidence across populations. Several studies in Africa have demonstrated that most *H. pylori* infections are of the virulent type as they were predominantly *cag*A and *vac*A s1 positive\[[@B66]-[@B68]\], therefore factors other than *H. pylori* virulence are likely of major importance in sub-Saharan Africa.

Environmental factors are essential in modulating *H. pylori* responses as well. There is a dietary component, with foods high in salt and low fruit intake increasing GCA risk. Both alcohol consumption and active tobacco smoking are also established risk factors\[[@B69],[@B70]\]. Regular consumption of fresh fruits and vegetables seems to delay the onset of AG\[[@B71],[@B72]\]. Further, co-infection of mice with *Heligosomoides polygyrus*, an extra-cellular mouse parasite, and *Helicobacter felis* has been shown to alter the immune response with down-regulation of Th1 dependent IgG2a serum antibody response to a greater extent than the Th2 dependent IgG1 antibody response leading to a reduction in *H. pylori*-induced gastric atrophy\[[@B73]\]. This suggests that other common infections in Africa might, likewise, affect the outcome of *H. pylori* infection. Differences in GCA rates between African countries and other parts of the world may accordingly be related to differences in intake of particular food, possibly co-existing infections or composition of gut microbiota. As with other infections, the natural history of *H. pylori* infection is determined by a range of microbe, host and environmental co-factors\[[@B74]\].

CONCLUSION
==========

PUD and pre-malignant lesions are not uncommon in Africa when compared with the West despite contrasting *H. pylori* prevalence. However, lack of cohort studies drawn from the general population make accurate evaluation of incidence of GDD in Africa elusive. Additionally, the lack of a temporal relationship with incidence of risk factors, such as *H. pylori* infection, prevents an assessment of the strength of such risks. Tertiary center studies are heterogenous between and within-countries, subject to selection bias and may not be generalizable to the wider population. Therefore, longitudinal studies are required to elucidate how a myriad of environmental factors and gut microbiota (*e.g*., helminthic infections) act synergistically with host and *H. pylori* in expression of gastro-duodenal phenotype in African countries. Evidence is still lacking to support (or not) the African enigma theory, due to this theory being based on inconsistent data that indicate a particularly low incidence of GDD in African countries.
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